From December 16th to December18th 2016, P4 China-International Precision Medicine Convention was held in Beijing successfully. There were 60 regulators, leading experts and well-known enterprise executives from home and abroad attended the convention. Dr. Wei, the CSO of EdiGene, was invited to attend the convention and made a speech.
Since the launch of US government’s Precision Medicine Initiative (PMI), China has also continuously strengthened its solid support for precision medicine. The Ministry of Science and Technology of the People’s Republic of China (MOST) has established National Precision Medicine Strategic Expert Committee as part of national strategy. The Chinese Academy of Sciences (CAS) also published its detailed guidance for projects under Chinese PMI, which is expected to be funded with 60 billion RMB by 2030. National Health and Family Planning Commission (NHFPC) has first announced its “lists of pilot institution for Tumor Clinical High-throughput Gene Sequencing Services”, and 20 institutions were enlisted. The speed outpaced the expectations of medical and financial community. In March 2016, China has initiated its precision medicine specific subjects, aiming at building big-data platform for major disease prevention, diagnosis and treatment from 2017 to 2019, as well as driving a batch of precise treatment and molecular diagnostic products into National Basic Medical Insurance Drug Catalog.
Meanwhile, personalized/precision medicine is the most extensive and rapid-growth subject in healthcare area in recent years, including genetics, clinical medicine, laboratory medicine, pathology, human genomics, pharmacogenomics and environmental factors, etc. Driven by variety of trends, like systems biology, ever-increasing network consumers and IT digital transformation, the era of P4 Medicine featured by Predictive, Personalized, Preventive, & Participatory is coming.
P4 China includes main conference focusing on precision medicine development opportunities & strategies, and 3 sub-forums-multi-omics and systems biology forum, molecular diagnostics forum and precise drug R&D forum.
EdiGene Inc. is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. We aim at providing high quality products and services for patients, pharmaceutical industry, diagnostic industry and scientific research community. EdiGene produces stable genome edited mammalian cell lines serving a wide-range of R&D activities in areas of basic research, diagnostic and therapeutic development. EdiGene’s Ready-Made KO Cells are utilized as Reference Standards in antibody KO validation for high quality antibody QC, as well as in diagnostic products. EdiGene provides Custom Genome Editing Service and CRISPR/Cas9 based High Throughput Genetic Screening Service to identify genes related to drug-sensitivity, drug-resistance, and synthetic lethality, and accelerate drug discovery and clinical trials.
The P4 China 2016 convention was held in the first year of the implementation of the national 13th five-year plan for precision medicine and the new era of 4P medicine (predictive, preventive, personalized and participatory). The convention has brought together professionals from government, industry, academia, research institutes and finance, helped to integrate different ideas from policy, supervision, finance, technology, clinical practices and business, and facilitated the development of precision medicine industry.